Newtopia AI Stock Analysis
Want to see TSE:NEWU.H full AI Analyst Report?
Newtopia (NEWU.H) AI Stock Analysis
Newtopia
(TSXV:NEWU.H)
No summary available
Newtopia (NEWU.H) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 866.33K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- -0.17
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Canada
- Employees
- 100
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Healthcare Information Services
Newtopia Business Overview & Revenue Model
Company Description
Newtopia Inc., a health technology company, delivers disease prevention solutions. It offers a personalized habit change platform that focuses on physical and mental health risk reduction. The company was incorporated in 2008 and is headquartered in...
How the Company Makes Money
Newtopia makes money primarily through subscription-based revenue models, where clients, including individuals and employers, pay for access to its personalized health improvement programs. The company partners with employers and health insurers who...
Newtopia Earnings Call Summary
The earnings call highlighted promising strategic partnerships and key client renewals, indicating strong potential for growth and profitability in the future. However, the company faced significant revenue declines and an EBITDA loss this quarter. Despite these challenges, the operational efficiencies and high engagement rates suggest a positive outlook.
Q3-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Q3 2024 earnings call for Newtopia Inc., key guidance was shared highlighting the company's strategic focus and financial metrics. Newtopia reported a revenue of $1.0 million for Q3 2024, down from $2.4 million in the prior year, primarily due to the loss of a client and structural changes at another existing client. Despite this, the company maintained a gross profit of $0.3 million, equating to 34% of revenue. The company is targeting profitability in 2025, supported by a new strategic partnership with a U.S. payvider to make its habit change platform available to workers at no out-of-pocket cost. Additionally, Newtopia achieved significant client engagement, with one Fortune 10 partner reaching 72% engagement and 30% of their population achieving a clinically significant weight loss. Newtopia aims to leverage these successes to drive growth through strategic partnerships and innovations in health AI, further improving outcomes and reducing costs for its clients.
Newtopia Peers Comparison
Overall Rating
TSE:NDAT45Neutral
TSE:CHS42.4Neutral
TSE:UDOC41Neutral
TSE:DMED39Underperform
TSE:AIDR38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 45Neutral | CAD 1.24M | -16.67 | -49.83% | ― | ― | 0.00% | |
| 42Neutral | CAD 9.86M | -1.47 | 64.52% | ― | 7.63% | -106.03% | |
| 41Neutral | CAD 4.32M | -1.33 | 355.56% | ― | 614.03% | 51.97% | |
| 39Underperform | CAD 3.29M | -1.61 | 739.84% | ― | ― | -28.35% | |
| 38Underperform | CAD 41.52M | -1.52 | -444.52% | ― | 415.06% | -54.80% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:NEWU.H | Newtopia, Inc. | 0.01 | 0.00 | 0.00% | |
| TSE:NDAT | nDatalyze Corp | 0.03 | 0.01 | 100.00% | |
| TSE:AIDR | Rocket Doctor Ai Inc | 0.41 | -0.37 | -47.44% | |
| TSE:CHS | Comprehensive Healthcare Systems Inc | 0.34 | -0.16 | -32.00% | |
| TSE:UDOC | Unidoc Health Corp. | 0.05 | -0.14 | -73.68% | |
| TSE:DMED | DiagnaMed Holdings Corp. | 0.03 | -0.05 | -64.29% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
